Paroxetine CR Augmentation for Posttraumatic Stress Disorder Refractory to Prolonged Exposure Therapy
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Little is known about the efficacy of "next step" strategies for patients with post-traumatic stress disorder (PTSD) who remain symptomatic despite treatment. This study prospectively examines the relative efficacy of augmentation of continued prolonged exposure therapy (PE) with paroxetine CR versus placebo for individuals remaining symptomatic despite a course of PE. METHOD: Adult outpatients meeting DSM-IV criteria for PTSD were recruited from February 2003 to September 2005 at 4 academic centers. Phase I consisted of 8 sessions of individual PE over a 4- to 6-week period. Participants who remained symptomatic, defined as a score of >or= 6 on the Short PTSD Rating Interview (SPRINT) and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score >or= 3, were randomly assigned to the addition of paroxetine CR or matched placebo to an additional 5 sessions of PE (Phase II). RESULTS: Consistent with prior studies, the 44 Phase I completers improved significantly with initial PE (SPRINT: paired t = 7.6, df = 41, p < .0001; CGI-S: paired t = 6.37, df = 41, p < .0001). Counter to our hypothesis, however, we found no additive benefit of augmentation of continued PE with paroxetine CR compared to pill placebo for the 23 randomly assigned patients, with relatively minimal further gains overall in Phase II. CONCLUSION: Although replication with larger samples is needed before definitive conclusions can be drawn, our data do not support the addition of paroxetine CR compared with placebo to continued PE for individuals with PTSD who remain symptomatic after initial PE, suggesting that the development of novel treatment approaches for PTSD refractory to PE is needed. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00215163.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“SSRIs: Evidence from meta-analyses [195-197] and RCTs supports the use of the SSRIs citalopram [198-200], fluoxetine [201-204], fluvoxamine [195,205-210], paroxetine [211-219], and sertraline [183,220,221,223,224] (all Level 1), as well as escitalopram [198] and paroxetine controlled-release (CR) [225] (both Level 2)…”
ResultInfluentialProlonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences - Therapist Guide
Foa, E., Hembree, E. A., Rothbaum, B. O., & Rauch, S. (2019) · doi:10.1093/med-psych/9780190926939.001.0001 · Cited by 412
Self-citationde Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.033 · Cited by 220
Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD)
Hetrick, S. E., Purcell, R., Garner, B., & Parslow, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007316.pub2 · Cited by 212
Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD
Zoellner, L. A., Roy-Byrne, P. P., Mavissakalian, M., & Feeny, N. C. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17090995 · Cited by 125
Metadata
- Authors
- Simon, N. M., Connor, K. M., Lang, A. J., Rauch, S., Krulewicz, S., LeBeau, R. T., Davidson, J. R. T., Stein, M. B., Otto, M. W., Foa, E. B., & Pollack, M. H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-03-15
- Volume
- 69
- Issue
- 3
- Pages
- 400-405
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2039999929
- Cited by
- 126
- References
- 0
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paroxetine CR Augmentation for Posttraumatic Stress Disorder Refractory to Prolonged Exposure Therapy. https://app.cochat.ai/papers/10.4088/jcp.v69n0309
- The paper
- Simon, N. M., Connor, K. M., Lang, A. J., Rauch, S., Krulewicz, S., LeBeau, R. T., Davidson, J. R. T., Stein, M. B., Otto, M. W., Foa, E. B., & Pollack, M. H. (2008). Paroxetine CR Augmentation for Posttraumatic Stress Disorder Refractory to Prolonged Exposure Therapy. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n0309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.